EquityFlow › Companies › Spirea

Spirea

Biotech · Cambridge, GB

Antibody-drug conjugate (ADC) cancer therapeutics developer

Funding history

Date	Round	Amount
Jun 2022	Seed Spirea, a Cambridge antibody-drug-conjugate biotech, raised £2.4M from UK and US investors.	$2.4M

Investors

Cambridge Enterprise

Similar companies in Biotech

Imperagen Haga Bioscience Pixelgen Technologies Gallant Chai Discovery SNIPR Biome Cellbox Labs Scope Biosciences GenLumina Actithera NUCLIDIUM Anocca

Explore funding flow on EquityFlow →